AmMax Bio. Revenue
Pharmaceutical Manufacturing • 
Redwood City, California, United States • 11-20 Employees
AmMax Bio. revenue & valuation
| Annual revenue | $1,026,660 |
| Revenue per employee | $86,000 |
| Estimated valuation?This valuation is estimated based on industry average for the Pharmaceutical Manufacturing industry and current estimated revenues | $3,300,000 |
| Total funding | No funding |
Key Contacts at AmMax Bio.
Michael Kavanaugh
Independent Director
John Varian
Member Board Of Directors
Dave Edwards
Director
Larry Hsu
Chief Executive Officer
Cynthia Sung
Executive Assistant To Chief Executive Officer
Company overview
| Headquarters | 333 Twin Dolphin Drive, Suite 370, Redwood City, California 94065, US |
| Website | |
| NAICS | 3254 |
| Keywords | AML, Oncology, ADC, Colorectal Cancer, Antibody-Drug Conjugates, Minimal Residual Disease, Tgct, Molecular Residual Disease |
| Founded | 2020 |
| Employees | 11-20 |
| Socials |
AmMax Bio. Email Formats
AmMax Bio. uses 1 email format. The most common is {first initial}{last name} (e.g., jdoe@ammaxbio.com), used 100% of the time.
| Format | Example | Percentage |
|---|---|---|
{first initial}{last name} | jdoe@ammaxbio.com | 100% |
About AmMax Bio.
AmMax Bio. is a private clinical-stage biotech company focused on the development of innovative cancer therapeutics. It leverages its expertise in translational science and drug development to pursue first-in-class or best-in-class therapeutics with significant market opportunity. AmMax was founded in 2020 out of a partnership with Amgen wherein AmMax licensed an exclusive worldwide right to a monoclonal antibody targeting the colony stimulating factor 1 receptor (CSF1R). As part of the transaction, Amgen took a minority ownership in the company. At the core of AmMax's pipeline are AMB-066 and AMB-104. AmMax is collaborating with MD Anderson to develop AMB-066, an mAb targeting CSF1R in Phase 2a for treating colorectal cancer minimal residual disease (CRC MRD). AMB-104 is a novel antibody-drug conjugate utilizing Synaffix's linker-payload platform and in development for treating acute myeloid leukemia (AML) and potentially solid tumors. AmMax has a very experienced management team, led by Dr. Larry Hsu, co-founder and former CEO of Impax Laboratories, Inc., which he successfully built into a fully integrated multi-billion dollar publicly traded pharmaceutical company. With broad experience across therapeutic areas and therapeutic modalities, the AmMax team is strong in execution and has collectively brought multiple BLAs, NDAs and MAAs to approval and commercialization. With a seasoned management team and a robust pipeline, AmMax is poised to grow into a leading biotech company. For more on AmMax Bio and its pipeline, please visit the Company’s website at: www.AmMaxBio.com.
Employees by Management Level
Total employees: 11-20
Seniority
Employees
Employees by Department
AmMax Bio. has 8 employees across 4 departments.
Departments
Number of employees
AmMax Bio. Tech Stack
Discover the technologies and tools that power AmMax Bio.'s digital infrastructure, from frameworks to analytics platforms.
Miscellaneous
JavaScript libraries
WordPress themes
Page builders
JavaScript libraries
Web servers
Font scripts
JavaScript libraries
Programming languages
Blogs
Hosting
United Kingdom
Italy
Türkiye
Frequently asked questions
4.8
40,000 users
